Amphastar Pharmaceuticals, Inc.

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Investigation Details

On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. Analysts expressed disappointment at the Company’s announcement and Amphastar has still not responded to the CRL.

Following this news, Amphastar’s stock price fell by $7.31 per share, or approximately 13% to close at $46.09 per share on November 7, 2024.